Alexion Pharmaceuticals, Inc. (ALXN) said, for fiscal 2020, the company now expects non-GAAP earnings per share in a range of $10.65 to $10.95, revised from prior guidance range of $10.45 to $10.75. Total revenues are now projected in a range of $5.55 billion to $5.60 billion, revised from prior guidance range of $5.23 billion to $5.33 billion.
Second quarter non-GAAP earnings per share was $3.11, an 18 percent increase from the second quarter of 2019. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $2.59, for the quarter. Analysts' estimates typically exclude special items.
Second quarter net product sales were $1.45 billion, compared to $1.20 billion in the second quarter of 2019. Analysts expected revenue of $1.28 billion for the quarter.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.